PMID- 35863864
OWN - NLM
STAT- MEDLINE
DCOM- 20220725
LR  - 20220923
IS  - 2056-5933 (Electronic)
IS  - 2056-5933 (Linking)
VI  - 8
IP  - 2
DP  - 2022 Jul
TI  - Impact of clinical domains other than arthritis on composite outcomes in 
      psoriatic arthritis: comparison of treatment effects in the SEAM-PsA trial.
LID - 10.1136/rmdopen-2022-002366 [doi]
LID - e002366
AB  - OBJECTIVE: We used the Study of Etanercept And Methotrexate in Combination or as 
      Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA) data set to examine 
      the impact of presence of enthesitis, dactylitis, nail disease and/or psoriasis 
      on treatment response in patients with early psoriatic arthritis (PsA). METHODS: 
      This post hoc analysis evaluated the effect of baseline Spondyloarthritis 
      Research Consortium of Canada (SPARCC) Enthesitis Index (EI), Leeds Enthesitis 
      Index (LEI), Leeds Dactylitis Index (LDI), modified Nail Psoriasis Severity Index 
      (mNAPSI) scores and body surface area (BSA) on composite outcomes of minimal 
      disease activity (MDA) responses, Psoriatic Arthritis Disease Activity Score 
      (PASDAS) low disease activity (LDA), PASDAS changes and Good Responses and 
      Disease Activity Index for Psoriatic Arthritis (DAPSA) scores at Week 24. 
      RESULTS: Overall, 851 patients completed the SEAM-PsA trial and were included in 
      the analysis. Baseline enthesitis (SPARCC EI>0 vs SPARCC EI=0 or LEI>0 vs LEI=0) 
      was not associated with improved outcomes. Baseline dactylitis (LDI>0 vs LDI=0) 
      was positively associated with improved MDA (OR: 1.4, p=0.0457), PASDAS LDA (OR: 
      1.8, p=0.0014) and Good Responses (OR: 1.6, p=0.0101) and greater reductions in 
      PASDAS (estimate: -0.9, p<0.0001) and DAPSA scores (estimate: -3.8, p=0.0155) at 
      Week 24. Similarly, baseline nail disease (mNAPSI >1 vs mNAPSI</=1) was positively 
      associated with improved MDA (OR: 1.8, p=0.0233) and PASDAS LDA (OR: 1.8, 
      p=0.0168) responses and greater reduction in PASDAS (estimate: -0.7, p=0.0005) at 
      Week 24. CONCLUSIONS: Results from our analysis suggest that presence of 
      dactylitis and nail disease, but not enthesitis, are associated with improved 
      outcomes in patients with early PsA who were treated with methotrexate and/or 
      etanercept.
CI  - (c) Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Helliwell, Philip S
AU  - Helliwell PS
AUID- ORCID: 0000-0002-4155-9105
AD  - Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, 
      Leeds, UK p.helliwell@leeds.ac.uk.
FAU - Mease, Phillip J
AU  - Mease PJ
AUID- ORCID: 0000-0002-6620-0457
AD  - Rheumatology Research, Swedish Medical Center and University of Washington, 
      Seattle, Washington, USA.
FAU - Kavanaugh, Arthur
AU  - Kavanaugh A
AD  - Division of Rheumatology, Allergy, and Immunology, University of California San 
      Diego, La Jolla, California, USA.
FAU - Coates, Laura C
AU  - Coates LC
AUID- ORCID: 0000-0002-4756-663X
AD  - Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, 
      University of Oxford, Oxford, UK.
FAU - Ogdie, Alexis
AU  - Ogdie A
AUID- ORCID: 0000-0002-4639-0775
AD  - Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 
      USA.
FAU - Deodhar, Atul
AU  - Deodhar A
AD  - Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, 
      Portland, Oregon, USA.
FAU - Strand, Vibeke
AU  - Strand V
AUID- ORCID: 0000-0003-4978-4072
AD  - Division of Immunology/Rheumatology, Stanford University, Palo Alto, California, 
      USA.
FAU - Kricorian, Gregory
AU  - Kricorian G
AD  - Clinical Development, Amgen Inc, Thousand Oaks, California, USA.
FAU - Liu, Lyrica X H
AU  - Liu LXH
AD  - Global Biostatistics, Amgen Inc, Thousand Oaks, CA, USA.
FAU - Collier, David
AU  - Collier D
AD  - Clinical Development, Amgen Inc, Thousand Oaks, California, USA.
FAU - Gladman, Dafna D
AU  - Gladman DD
AUID- ORCID: 0000-0002-9074-0592
AD  - Centre for Prognosis Studies in The Rheumatic Diseases, University of Toronto, 
      Toronto, Ontario, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - RMD Open
JT  - RMD open
JID - 101662038
RN  - OP401G7OJC (Etanercept)
RN  - YL5FZ2Y5U1 (Methotrexate)
SB  - IM
MH  - *Arthritis, Psoriatic/complications/diagnosis/drug therapy
MH  - *Enthesopathy/drug therapy/etiology
MH  - Etanercept/therapeutic use
MH  - Humans
MH  - Methotrexate/therapeutic use
MH  - *Nail Diseases
MH  - Treatment Outcome
PMC - PMC9310247
OTO - NOTNLM
OT  - Antirheumatic Agents
OT  - Arthritis
OT  - Methotrexate
OT  - Tumor Necrosis Factor Inhibitors
COIS- Competing interests: PSH has received grant/research support and/or 
      speaker/honoraria from AbbVie, Novartis, Janssen and Pfizer. PJM has received 
      research grants and has served as a consultant or has been a speaker for AbbVie, 
      Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Gilead, 
      GlaxoSmithKline, Janssen, Novartis, Pfizer, SUN Pharma and UCB. AK declares no 
      conflicts for this work. LCC has received grants/research support from AbbVie, 
      Amgen, Celgene, Eli Lilly, Janssen, Novartis and Pfizer; has worked as a paid 
      consultant for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, 
      Celgene, Eli Lilly, Gilead, Galapagos, Janssen, Novartis, Pfizer and UCB; and has 
      been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, 
      Gilead, Janssen, medac, Novartis, Pfizer and UCB. AO has received research grants 
      from AbbVie, Novartis and Pfizer to University of Pennsylvania and Amgen to 
      FORWARD/NDB; has received consulting fees from AbbVie, Amgen, Bristol Myers 
      Squibb, Celgene, CorEvitas, Gilead, Janssen, Lilly, Novartis, Pfizer and UCB; and 
      reports receipt of royalties from Novartis (to spouse). AD has received research 
      grants from AbbVie, GlaxoSmithKline, Novartis, Pfizer and UCB and has received 
      consulting fees from AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, 
      Celgene, Gilead, GlaxoSmithKline, Janssen, Novartis, Pfizer and UCB. VS has 
      received consulting fees from AbbVie, Amgen, Arena, Aria, AstraZeneca, Bayer, 
      Bioventus, Bristol Myers Squibb, Boehringer Ingelheim, Celltrion, Corrona, 
      Crescendo/Myriad, EMD Serono, Equillium, Flexion, Genentech/Roche, Glenmark, GSK, 
      Horizon, Inmedix, Janssen, Kypha, Eli Lilly, Merck, Novartis, Pfizer, Regeneron, 
      Samsung, Sandoz, Sanofi, Servier, Setpoint and UCB. GK is an employee of and owns 
      stock in Amgen. DC is an employee of and owns stock in Amgen. LXHL is an employee 
      of and owns stock in Amgen. DDG has received research grants from Amgen, AbbVie, 
      Celgene, Eli Lilly, Janssen, Novartis, Pfizer and UCB and has received consulting 
      fees from Amgen, AbbVie, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, 
      Galapagos, Janssen, Novartis, Pfizer and UCB.
EDAT- 2022/07/22 06:00
MHDA- 2022/07/26 06:00
PMCR- 2022/07/21
CRDT- 2022/07/21 21:05
PHST- 2022/03/24 00:00 [received]
PHST- 2022/05/18 00:00 [accepted]
PHST- 2022/07/21 21:05 [entrez]
PHST- 2022/07/22 06:00 [pubmed]
PHST- 2022/07/26 06:00 [medline]
PHST- 2022/07/21 00:00 [pmc-release]
AID - rmdopen-2022-002366 [pii]
AID - 10.1136/rmdopen-2022-002366 [doi]
PST - ppublish
SO  - RMD Open. 2022 Jul;8(2):e002366. doi: 10.1136/rmdopen-2022-002366.